XSTRAHL LIMITED

Xstrahl is a global medical device manufacturer specializing in superficial and orthovoltage X-ray radiation therapy systems for clinical and preclinical research applications. The company delivers non-invasive radiation therapy equipment designed to treat non-melanoma skin cancers (basal cell and squamous cell carcinoma), benign dermatological conditions (keloid scarring, Dupuytren's contracture, Ledderhose disease), and palliative care indications. Xstrahl's clinical product line includes the Xstrahl 100, 150, 200, and 300 systems, along with the newer Radiant Aura platform with XBeam treatment planning software. These devices enable office-based and clinic-based treatment delivery by radiation oncologists and dermatologists with treatment outcomes comparable to surgical alternatives. The company also offers radiation research systems for translational research, enabling life science investigators, radiation physicists, and clinicians to conduct clinically relevant experiments. Xstrahl operates globally with North American headquarters in Suwanee, Georgia, and regional operations in the UK and Germany. The systems feature water-cooling technology, multiple energy levels (superficial and intermediate energies), user-friendly interfaces, and high reliability. Xstrahl supports the clinical and research community through educational resources, case studies, publications, presentations, and technical support services. The company positions itself as a leader in expanding access to non-invasive radiation therapy and advancing new treatment applications beyond traditional oncology.